Pharma channel feed

In­cyte nabs 2nd ever ap­proval ahead of sched­ule as FDA in­sists it can still re­view on time

6 years ago
FDA+

With third FDA ap­proval, Seat­tle Ge­net­ics plans vir­tu­al launch of metasta­t­ic breast can­cer drug amid coro­n­avirus pan­dem­ic

6 years ago
FDA+

FDA stamps OK on Uro­Gen's chemo gel — putting Liz Bar­rett and team's com­mer­cial chops to test amid pan­dem­ic

6 years ago
FDA+

Plough­ing through a crowd­ed PD-(L)1 mar­ket, BeiGene loads up on promis­ing lung can­cer da­ta

6 years ago
R&D
China

Q&A: An­a­lyst-turned biotech ex­ec-turned an­a­lyst reads the biotech Q1 tea leaves

6 years ago
People
R&D

As­traZeneca, Mer­ck win quick OK for a rare dis­ease drug — as the FDA de­clares it can still move fast dur­ing a crip­pling pan­dem­ic

6 years ago
FDA+

Hunt­ing a full OK for Baven­cio in front­line blad­der can­cer, Pfiz­er, Mer­ck KGaA re­ceive VIP treat­ment at FDA

6 years ago
FDA+

Bris­tol My­ers Squibb, Ac­celeron rack up sec­ond OK for Re­blozyl, on­to block­buster sta­tus

6 years ago
FDA+

Ramp­ing up glob­al pro­duc­tion of remde­sivir, Gilead CEO Dan O’Day de­tails plans to dis­trib­ute 1.5M dos­es to fight Covid-19 — for free

6 years ago
Coronavirus

Mer­ck scores new ad­vance on tu­mor-ag­nos­tic front as Keytru­da beat chemo-based reg­i­mens in a type of col­orec­tal can­cer

6 years ago
R&D

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

6 years ago
R&D

As­traZeneca gets a green light on Imfinzi for small-cell lung can­cer — set­ting the stage for a bat­tle with Roche's Tecen­triq

6 years ago
FDA+

Bris­tol My­ers bags a long-await­ed FDA OK for ozan­i­mod — but the pan­dem­ic will keep it off the mar­ket

6 years ago
FDA+

Af­ter crit­ics lam­bast­ed Gilead for grab­bing the FDA's spe­cial rare drug sta­tus on remde­sivir, they're giv­ing it back

6 years ago
FDA+
Coronavirus

Bay­er fires em­ploy­ee who was spot­ted break­ing quar­an­tine in Chi­na

6 years ago
China
Coronavirus

An­oth­er an­tibi­ot­ic mak­er bites the dust, as Tetraphase is swal­lowed for cheap

6 years ago
Deals

Intar­ci­a's speed bump at the FDA turns in­to a road­block, as reg­u­la­tors once again turn thumbs down on di­a­betes drug/de­vice

6 years ago
R&D

Bris­tol My­ers backs a Eu­ro­pean VC's record-set­ting biotech ven­ture fund, which tops out at $600M

6 years ago
R&D

Nine new coro­n­avirus cas­es are tied to the Bio­gen out­break — as in­fec­tions spread to 'close con­tact­s'

6 years ago
People
Coronavirus

FDA ap­proves ex-No­var­tis drug for Cush­ing’s dis­ease

6 years ago

As Bio­gen grap­ples with coro­n­avirus cri­sis, Big Phar­mas like Eli Lil­ly, Take­da hun­ker down, tell staffers to work from home

6 years ago
Coronavirus

Eu­ro­pean reg­u­la­tors ex­pand use of Ab­b­Vie's two-month hep C reg­i­men

6 years ago

As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

6 years ago
R&D

More than half of its gross sales ul­ti­mate­ly went to pay­ers as re­bates, Sanofi says

6 years ago
First page Previous page 254255256257258259260 Next page Last page
A service from the Financial Times